• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Interim CEO Greiner Michael was granted 34,316 shares, increasing direct ownership by 18% to 224,264 units (SEC Form 4)

    3/11/25 4:54:56 PM ET
    $AVNS
    Industrial Specialties
    Health Care
    Get the next $AVNS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Greiner Michael

    (Last) (First) (Middle)
    5405 WINDWARD PKWY

    (Street)
    ALPHARETTA GA 30004

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    AVANOS MEDICAL, INC. [ AVNS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Interim CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    03/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/07/2025 A 34,316(1) A $0 224,264 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $15.24 03/07/2025 A 73,633 (2) 03/07/2035 Common Stock 73,633 $0 73,633 D
    Explanation of Responses:
    1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 7, 2026, 1/3 on March 7, 2027 and 1/3 on March 7, 2028. Each TRSU is the economic equivalent of one share of Common Stock.
    2. The award will vest 30% on March 7, 2026, 30% on March 7, 2027 and 40% on March 7, 2028.
    Remarks:
    /s/ Mojirade James, as attorney-in-fact for Michael C. Greiner 03/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVNS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVNS

    DatePrice TargetRatingAnalyst
    7/25/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    5/22/2023$31.00Buy
    CL King
    2/24/2022$47.00 → $41.00Overweight
    Keybanc
    1/7/2022$37.00 → $36.00Underweight
    Morgan Stanley
    8/4/2021$45.00 → $41.00Underweight
    Morgan Stanley
    8/4/2021$60.00 → $45.00Overweight → Equal-Weight
    Stephens
    8/4/2021$55.00 → $47.00Overweight
    Keybanc
    More analyst ratings

    $AVNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Pickett Jason Marc claimed ownership of 40,113 shares (SEC Form 3)

      3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/29/25 3:45:04 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Amendment: New insider Pacitti David claimed ownership of 242,047 shares (SEC Form 3)

      3/A - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/24/25 5:00:37 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • New insider Pacitti David claimed ownership of 242,047 shares (SEC Form 3)

      3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/24/25 12:08:46 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Shimer Julie Ann bought $9,925 worth of shares (500 units at $19.85), increasing direct ownership by 1% to 50,090 units (SEC Form 4)

      4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      3/11/24 5:15:37 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avanos Medical, Inc. Announces First Quarter 2025 Results

      ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

      5/6/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

      4/28/25 7:47:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Expands Direct Operations for MIC-KEY* Enteral Feeding Products in the UK starting July 2025

      ZAVENTEM, Belgium, April 2, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a global medical technology company, today announced that it will take direct responsibility for the sales and distribution of its MIC-KEY enteral feeding products in the United Kingdom, effective 25 July 2025. This strategic move reflects Avanos' commitment to prioritizing customer needs, enhancing product availability into the future, and providing a seamless experience for healthcare providers and patients. For the past 29 years, Vygon UK, a leading supplier of surgical and medical devices has

      4/2/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Financials

    Live finance-specific insights

    See more

    $AVNS
    Leadership Updates

    Live Leadership Updates

    See more
    • Avanos Medical, Inc. Announces First Quarter 2025 Results

      ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

      5/6/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

      4/28/25 7:47:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results

      ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil

      2/26/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer

      ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support

      3/17/25 7:30:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Appoints Indrani Franchini to Board of Directors

      ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it

      7/1/24 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain

      ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ

      5/13/24 7:15:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avanos Medical downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight

      7/25/23 6:15:12 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • CL King initiated coverage on Avanos Medical with a new price target

      CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00

      5/22/23 8:52:10 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Keybanc reiterated coverage on Avanos Medical with a new price target

      Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously

      2/24/22 4:48:01 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avanos Medical Inc.

      SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)

      11/14/24 1:28:34 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

      SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

      2/14/24 11:41:02 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

      SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

      2/13/24 4:58:57 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avanos Medical Inc.

      10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)

      5/6/25 4:17:36 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

      5/6/25 7:07:11 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

      4/30/25 9:47:43 AM ET
      $AVNS
      Industrial Specialties
      Health Care